Muffaddal Morkas, MD
Hematology & Oncology · Houston, TXNPI 1235168808
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 37.2% of the total. 2025 is the largest year on record at $7,245, more than ten times the $28 reported in 2019.
Across 151 payments — averaging $61.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$3K
- Johnson & Johnson$3K
- Pfizer$450
- Sanofi$266
- Novartis$235
- Gilead$176
- plus $2K from 33 others
Across 37 payments — averaging $4219.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$69K
- AstraZeneca$45K
- Eli Lilly$25K
- E.r. Squibb & Sons, L.L.C.$17K
What the payments were for
- Consulting fees$4,20346%
- Travel & lodging$1,28914%
- Food & beverage$3,41837%
- Education$3143%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 7 | $3,433 |
| Johnson & Johnson | 20 | $2,683 |
| Pfizer | 19 | $450 |
| Sanofi | 10 | $266 |
| Novartis | 9 | $235 |
| Gilead(2 entities) | 8 | $176 |
| AstraZeneca | 5 | $170 |
| GSK | 6 | $150 |
| Bayer | 5 | $136 |
| Astellas Pharma US Inc | 7 | $132 |
| Merck | 6 | $124 |
| Medtronic | 1 | $108 |
| Bristol Myers Squibb | 4 | $105 |
| Daiichi Sankyo Inc. | 3 | $85 |
| Array Biopharma Inc | 4 | $80 |
| Karyopharm Therapeutics Inc. | 3 | $66 |
| Incyte Corporation | 3 | $66 |
| Springworks Therapeutics, Inc. | 2 | $64 |
| AbbVie | 3 | $62 |
| Stemline Therapeutics Inc. | 2 | $58 |
| Beigene USA, Inc. | 2 | $55 |
| Boston Scientific | 1 | $54 |
| Tempus AI, Inc | 2 | $52 |
| Rigel Pharmaceuticals, Inc. | 2 | $52 |
| Taiho Oncology, Inc. | 2 | $40 |
| Immunocore Limited | 1 | $33 |
| Tersera Therapeutics LLC | 1 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| EMD Serono, Inc. | 1 | $27 |
| ADC Therapeutics America, Inc. | 1 | $26 |
| CTI Biopharma Corp. | 1 | $24 |
| Iovance Biotherapeutics, Inc. | 1 | $24 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Amgen | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DARZALEX$2,274
- LORBRENA$124
- OSTEOCOOL RF ABLATION SYSTEM$108
How this compares
$9,223 in reported general payments places this provider in the 70th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 81 | $963,096 |
| CalquenceAcalabrutinib Maleate | 38 | $571,545 |
| RevlimidLenalidomide | 32 | $506,962 |
| BrukinsaZanubrutinib | 23 | $343,627 |
| TukysaTucatinib | 13 | $301,790 |
| ImbruvicaIbrutinib | 13 | $212,756 |
| GilotrifAfatinib Dimaleate | 11 | $129,679 |
| EliquisApixaban | 110 | $91,597 |
| XareltoRivaroxaban | 39 | $40,185 |
| Octreotide Acetate | 12 | $4,944 |
| Dexamethasone | 48 | $1,008 |
| Anastrozole | 40 | $760 |
| Duloxetine Hcl | 47 | $686 |
| Acyclovir | 74 | $609 |
| Levothyroxine Sodium | 62 | $562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $66 | $963,09681 claims |
| AstraZenecaCalquence | $170 | $571,54538 claims |
| Bristol Myers SquibbRevlimid | $105 | $506,96232 claims |
| Beigene USA, Inc.Brukinsa | $55 | $343,62723 claims |
| Boehringer IngelheimGilotrif | $14 | $129,67911 claims |
| PfizerEliquis | $450 | $91,597110 claims |
| Johnson & JohnsonXarelto | $2,683 | $40,18539 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $29 | $56262 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.